23andMe Founder Plans $305M Buyback with Enhanced Data Protections

Anne Wojcicki, co-founder of 23andMe, has successfully reclaimed control of the genetic testing company through her nonprofit, TTAM Research Institute, which won a bankruptcy auction with a $305 million bid, surpassing Regeneron's $256 million offer. TTAM's acquisition includes 23andMe's Personal Genome Service, Research Services, and telehealth subsidiary Lemonaid Health, and is subject to approval by the U.S. Bankruptcy Court for the Eastern District of Missouri. The nonprofit has committed to upholding 23andMe's existing privacy policies while introducing enhanced consumer protections such as customers' rights to delete data, opt out of research, identity theft monitoring, and assurances against future data sales without consent. The deal represents a significant recovery for 23andMe, which filed for Chapter 11 bankruptcy earlier in 2025 after struggling with revenue generation and privacy breaches affecting millions of customers. Wojcicki expressed enthusiasm about continuing 23andMe's mission under TTAM to help people access and benefit from human genomic information. The transaction is anticipated to close in the coming weeks following court approval.